*Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours.
†FreeStyle Libre 2 system: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
‡FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
§Data based on the number of users worldwide for FreeStyle Libre family of personal CGMs compared to the number of users for other leading personal CGM brands and based on CGM sales dollars compared to other leading personal CGM brands.
IIThe FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView.
#Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
**FreeStyle Libre 2 system is indicated for use in people with diabetes age 4 and older.
††Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.
‡‡Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
§§Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life.
II II or ♢Eligible patients will receive one (1) FreeStyle Libre 14 day sensor or one (1) FreeStyle Libre 2 sensor and reader at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is not available for patients with gestational diabetes. Only patients 18 and older are eligible to receive an offer for the FreeStyle Libre 14 day sensor, and patients 4 and older are eligible to receive an offer for the FreeStyle Libre 2 sensor and reader. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs or residents of Massachusetts, Puerto Rico and other US territories. The free FreeStyle Libre 14 day sensor or FreeStyle Libre 2 sensor and reader is provided as a sample and is limited to one NDC per eligible person. The FreeStyle Libre 14 day sensor or FreeStyle Libre 2 sensor and reader cannot be re-sold, traded nor submitted to any third party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
References: 1. The Endocrine Society. Continuous Glucose Monitoring: Connecting the Dots. Washington, DC: The Endocrine Society, 2020. 2. Reddy, Nihaal, Neha Verma, and Kathleen Dungan. "Monitoring Technologies- Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control". [Updated 2020 Aug 16]. In: Feingold, Kenneth R, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279046/. 3. Campbell, Fiona M., et al. “Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study.” Pediatr Diabetes 19, no. 7 (November 2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 4. FreeStyle Libre 2 User's Manual. 5. Haak, Thomas, et al. “Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial.” Diabetes Therapy 8, no. 1 (February 2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6. 6. Data on file. Abbott Diabetes Care.
ADC-06051 Ver 6.0 04/21